To determine the objective response rate (CR+PR) of single agent LY2606368, a second-generation Chk 1/2 inhibitor, in women with gBRCAm-associated breast and ovarian cancers, and HGSOC and TNBC at low genetic risk and mCRPC

153

All

18 Years to 99 Years (Adult, Senior)

NCT02203513

14015614-C-0156

July 29, 2014

June 4, 2018

June 3, 2019

July 30, 2014

February 6, 2018

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland, United States